Remdesivir（开发代码GS-5734）是一种抗病毒药，一种新型的核苷酸类似物前药。 它是由吉利德科学公司（Gilead Sciences）开发的，用于治疗埃博拉病毒病和马尔堡病毒感染，尽管后来也发现它对更远距离相关的病毒（如呼吸道合胞病毒，胡宁病毒，拉沙热病毒和MERS）显示出合理的抗病毒活性。 -冠状病毒。[1] 可能会对抗其他冠状病毒，例如SARS [2]和潜在的2019-nCoV感染[3]。 它还可能有助于防止Nipah和Hendra病毒感染。[4] [5]
内容
1 埃博拉病毒临床试验
2 新型冠状病毒（2019-nCoV）
3 参考
抗埃博拉病毒的临床试验
由于2013-2016年西非埃博拉病毒的流行，Remdesivir迅速地通过了临床试验，尽管当时处于早期发展阶段，但最终仍在至少一名人类患者中使用。初步结果令人鼓舞，并将其用于2018年开始的基伍埃博拉疫情的紧急情况以及进一步的临床试验，直到2019年8月刚果健康官员宣布与单克隆抗体治疗（例如mAb114和REGN）相比无效-EB3****。[6] [7] [8] [9] [10] [11] [12] [13]
新型冠状病毒（2019-nCoV）
为了应对由2019-nCoV冠状病毒引起的2019-20年度武汉冠状病毒暴发，吉利德与中国医学机构合作，将雷姆昔韦用于“少数病人”研究其效果。 [14]吉利德还开始针对2019-nCoV进行瑞德昔韦的实验室测试。吉利德表示，雷姆昔韦在非人类动物中“显示出对SARS和MERS的活性”。[15]
另见
Galidesivir
MK-608
NITD008
参考
Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al. (March 2018). "Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease". mBio. 9 (2). doi:10.1128/mBio.00221-18. PMC 5844999. PMID 29511076.
Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, Leist SR, Pyrc K, Feng JY, Trantcheva I, Bannister R, Park Y, Babusis D, Clarke MO, Mackman RL, Spahn JE, Palmiotti CA, Siegel D, Ray AS, Cihlar T, Jordan R, Denison MR, Baric RS (June 2017). "Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses". Science Translational Medicine. 9 (396). doi:10.1126/scitranslmed.aal3653. PMC 5567817. PMID 28659436.
"Coronavirus Vaccine Candidate Eyed for Human Trials by April". 22 January 2020. Retrieved 23 January 2020.
"Experimental Ebola drug 'remdesivir' may help protect against Nipah virus, say scientists". 3 June 2019.
"Scientists Claim Drug Designed to Beat Ebola Also Fights Off Nipah". 2 June 2019.
Preidt R (June 29, 2017). "Experimental Drug Shows Promise Against Dangerous Viruses: Medicine worked in lab tests against germs that cause SARS and MERS infections". Archived from the original on 28 July 2017.
Cihlar T (20 October 2015). "Discovery and Development of GS-5734, a Novel Nucleotide Prodrug with Broad Spectrum Anti-Filovirus Activity". FANG-WHO Workshop, Fort Detrick, MD. Gilead Sciences.
Warren T, Jordan R, Lo M, Soloveva V, Ray A, Bannister R, et al. (Fall 2015). "Nucleotide Prodrug GS-5734 Is a Broad-Spectrum Filovirus Inhibitor That Provides Complete Therapeutic Protection Against the Development of Ebola Virus Disease (EVD) in Infected Non-human Primates". Open Forum Infect Dis. 2. doi:10.1093/ofid/ofv130.02.
Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. (March 2016). "Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys". Nature. 531 (7594): 381–5. Bibcode:2016Natur.531..381W. doi:10.1038/nature17180. PMC 5551389. PMID 26934220.
Jacobs M, Rodger A, Bell DJ, Bhagani S, Cropley I, Filipe A, et al. (July 2016). "Late Ebola virus relapse causing meningoencephalitis: a 病例报告". Lancet. 388 (10043): 498–503. doi:10.1016/S0140-6736(16)30386-5. PMC 4967715. PMID 27209148.
"Ebola Treatment Trials Launched In Democratic Republic Of The Congo Amid Outbreak". NPR.org. Retrieved 2019-05-28.
McNeil, Jr., Donald G. (12 August 2019). "A Cure for Ebola? Two New Treatments Prove Highly Effective in Congo". The New York Times. Retrieved 13 August 2019.
Molteni M (12 August 2019). "Ebola is Now Curable. Here's How The New Treatments Work". Wired. Retrieved 13 August 2019.
"Gilead mulls repositioning failed Ebola drug in China virus". Fierce Biotech. Retrieved 31 January 2020.
Joseph, Saumya Sibi; Samuel, Maju (2020-01-31). "Gilead working with China to test Ebola drug as new coronavirus treatment". Thomson Reuters. Archived from the original on 2020-01-31. Retrieved 2020-01-31. |
